Source-grounded facts extracted from KALA BIO, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
KALA BIO, Inc. reported financial results for the quarter and year ended December 31, 2022.
“On March 3, 2023, Kala Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2022 and provided a general business update.”
KALA BIO, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at $40,000,000 (effective 2023-01-19).
“On January 19, 2023, Kala Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into an Open Market Sale Agreement SM (the “ Sales Agreement ”) with Jefferies LLC, as agent (“ Jefferies ”), pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share (the “ Common Stock ”), from time to time through Jefferies.”
KALA BIO, Inc. amended term loan with Oxford Finance LLC.
“Pursuant to the Loan Amendment, the Company agreed (A) to make partial prepayments of the principal amount of the term loan outstanding under the Loan Agreement as follows (the “Prepayments”): (1) a payment of $5,000,000 on or before June 30, 2023, representing a partial prepayment of principal in the amount of $4,672,897.20, plus a final payment fee of $327,102.80 and (2) a payment of $5,000,000 on or before January 31, 2024, representing a partial prepayment of principal in the amount of $4,672,897.20, plus a final payment fee of 327,102.80 and (B) the start date for the Company to make amortization payments under the Loan Agreement shall be changed from January 1, 2026 to January 1, 2025 (the “Amortization Date”).”
KALA BIO, Inc. amended Loan Amendment with Oxford Finance LLC (effective 2022-12-27).
“On December 27, 2022, Kala Pharmaceuticals, Inc. (the “Company”) and Combangio, Inc., a wholly-owned subsidiary of the Company, entered into an amendment (the “Loan Amendment”) with Oxford Finance LLC to the Loan and Security Agreement, dated May 4, 2021 (as amended, the “Loan Agreement”), by and among the Company, Combangio, Inc. and Oxford Finance LLC, in its capacity as lender (in such capacity, the “Lender”), and in its capacity as collateral agent (in such capacity, the “Agent”).”
KALA BIO, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C), 5810(c)(3)(D)).
“December 5, 2022, Kala Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”) for continued listing on the Nasdaq Global Select Market, as the market value of the Company’s publicly held shares was less than $15,000,000 for each of the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Compan”
KALA BIO, Inc.: Filed Certificate of Elimination to remove all matters related to Series D Preferred Stock and reclassify shares as undesignated preferred stock (effective 2022-11-28).
“On November 28, 2022, immediately prior to filing the Certificate of Designation referenced above, the Company filed a Certificate of Elimination of Number of Shares of Preferred Stock Designated as Series D Preferred Stock (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware which, effective upon filing, eliminated all matters set forth in the Certificate of Designation of Series D Preferred Stock previously filed by the Company and all shares of Preferred Stock previously designated as Series D Preferred Stock resumed their status as undesignated shares of preferred stock of the Company.”
KALA BIO, Inc.: Filed Certificate of Designations to establish Series E Convertible Non-Redeemable Preferred Stock (effective 2022-11-28).
“On November 28, 2022 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series E Preferred Stock.”
KALA BIO, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at aggregate gross proceeds of up to $31.0 million (effective 2022-11-28).
“On November 28, 2022, Kala Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement priced at-the-market under Nasdaq rules, shares (the “Common Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”) and shares (the “Preferred Shares”, and together with the Common Shares, the “Private Placement Shares”) of Series E Convertible Non-Redeemable Preferred Stock, par value $0.001 per share, of the Company (the “Series E Preferred Stock”), in two tranches for aggregate gross proceeds of up to $31.0 million (collectively, the “Private Placement”).”
KALA BIO, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 8, 2022, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022”
Marjan Farid, M.D. was appointed as Class I director at KALA BIO, Inc..
“On October 31,, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of Kala Pharmaceuticals, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Marjan Farid, M.D. as a member of the Board, effective immediately.”
Mark Iwicki changed role as President at KALA BIO, Inc..
“Mark Iwicki will continue to lead the Company as its Chief Executive Officer and as Chairman of the Board of Directors but will no longer serve as President of the Company.”
Todd Bazemore was appointed as President and Chief Operating Officer at KALA BIO, Inc..
“On December 16, 2021, the Board of Directors of Kala Pharmaceuticals, Inc. (the “Company”) appointed Todd Bazemore, the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Operating Officer, effective immediately.”
Mark Blumenkranz was appointed as Director at KALA BIO, Inc..
“Upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”), the Board appointed Mark Blumenkranz as a member of the Board, effective upon the Closing of the Acquisition”
C. Daniel Myers was appointed as member of the Board of Directors at KALA BIO, Inc..
“On October 15, 2021, upon the recommendation of the Nominating and Corporate Governance Committee, the Board appointed C. Daniel Myers as a member of the Board, effective immediately, to fill the vacancy created by the resignation of Mr. Shah.”
Rajeev Shah resigned as member of the Board of Directors at KALA BIO, Inc..
“On October 14, 2021, Rajeev Shah notified Kala Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), which resignation was effective on October 15, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.